Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

Journal of the American Medical Association

Volumn 283, Issue 15, 2000, Pages 1967-1975

  Davis, Barry R ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CHLORTALIDONE; DOXAZOSIN; LISINOPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STROKE;

EID: 0034685403     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.15.1967     Document Type: Article

References (23)

1. Davis BR, Cutler JA, Gordon D, et al, for the ALLHAT Research Group. Rationale and design of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996; 9:342-360.
2. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Regression. New York, NY: Springer-Verlag; 1997.
3. Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical Trials. Boca Raton, Fla: Chapman & Hall/CRC Press; 2000.
4. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663.
5. Davis BR, Hardy RJ. Upper bounds for type I and type II error rates in conditional power calculations. Comm Stat. 1990;A19:3571-3584.
6. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314: 1547-1552.
7. Kostis J, Davis BR, Cutler JA, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-216.
8. Hansson L, Lindholm L, Ekbom T, et al, for the STOP-Hypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients With Hypertension-2 Study. Lancet. 1999;354:1751-1756.
9. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
10. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
11. Hypertension and Detection Follow-up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension and Detection Follow-up Program. Hypertension. 1984;6 (suppl 1):198-206.
12. Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000.
13. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
14. Wilson PW. From hypertension to heart failure: what have we learned? Clin Cardiol. 1999;22:V1-V10.
15. Li K, He H, Li C, Sirois P, Rouleau JL. Myocardial alpha-1-adrenoreceptor: inotropic effect and physiologic and pathologic implications. Life Sci. 1997;60: 1305-1318.
16. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999; 341:1276-1283.
17. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91:698-706.
18. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation. 1997;95:2007-2014.
19. Grimm RH Jr, Flack JM, Schoenberger JA, Gonzalez NM, Liebson PR. Alpha-blockade and thiazide treatment of hypertension: a double-blind randomized trial comparing doxazosin and hydrochlorothiazide. Am J Hypertens. 1996;9:445-454.
20. Ibsen H, Rasmussen K, Jensen HA, Leth A. Changes in plasma volume and extracellular fluid volume after addition of prazosin to propranolol treatment in patients with hypertension. Scand J Clin Lab Invest. 1978; 38:425-429.
21. Leenen FHH, Smith DL, Faraks RM, Reeves RA, Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive patients. Am J Med. 1987;82:969-978.
22. White M, Fourney A, Mikes E, Leenen FH. Effect of age and hypertension on cardiac responses to the alpha1-agonist phenylephrine in humans. Am J Hypertens. 1999;12:151-158.
23. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-2446.